Celgene posts impressive IIb data on psoriasis

One of Celgene's mid-stage drug prospects may be getting closer scrutiny from analysts now that it's turned in promising results in a mid-stage clinical trial for psoriasis. In the trial, 41 percent of the patients in the drug arm registered a 75 percent improvement in the symptoms of psoriasis--the PASI-75 score--compared with only 6 percent of the placebo arm with a similar response. And that positions the experimental apremilast--an oral drug--as a contender with Amgen's blockbuster injectable Enbrel, the dominant drug in this market.  

Enbrel's PASI-75 score is up to 47 percent. "The expectation going into this study was that apremilast would show efficacy well below that of the anti-TNFs, and thus this is a positive surprise," Geoff Meacham, an analyst at J.P. Morgan, tells Reuters. "These mid-stage data indicates that apremilast could hit $500 million in annual sales."

Celgene recruited 352 patients for the Phase IIb trial. The drug arm was treated with a 30-milligram dose. "These results are extremely important," said Kim Papp, M.D., Ph.D. of Probity Medical Research, Canada. "The results suggest apremilast is active and may meet a significant unmet medical need: a new oral treatment for patients with moderate-to-severe psoriasis."

Celgene VP Randall Stevens says the drug is ready for pivotal trials. The market, though, barely stifled a yawn. Celgene's shares dipped after the release.

- check out Celgene's release
- here's the story from Reuters

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.